ON EMERGING OPPORTUNITIES
Integrative research means our extensive company research informs every thesis and perspective. The result is deep industry knowledge, expertise, and trend insights that yield valuable results for our partners and clients.
- We believe the worldwide effort to develop treatments and vaccines for COVID-19 will help transform global vaccine capabilities and be a catalyst to drive new, more productive technology platforms forward to commercialization.
- The effort to approve and produce vaccines and treatments will provide an additional tailwind on top of already healthy growth in the pharma service and technology sector.
- Given the urgent nature and large volume of any resulting vaccines, we assume they will face extreme price pressure and limited margins. Therefore, on a risk adjusted basis we think the companies best positioned to grow and profit as a result of these efforts are the providers of services and technology - the picks and shovels of the efforts - where productivity and technology tend to be rewarded.
TABLE OF CONTENTS
Who are the players?
Wars and races drive innovation and opportunity
But it's not just vaccines
Select COVID-19 partnerships in the sector
Interesting times ahead
Process technology outperforms major indices, rallies to annual high
Process technology M&A loses steam
Process technology private investment slows during 1H20
In our first Process Technology Quarterly Insights report, it is nearly impossible to not review the healthcare oriented players in the space and how they contribute to the war on COVID-19. The current effort to address the pandemic serves as an example of the power and flexibility of the evolving pharma technology and services sector, from fundamental research to packaging of drug product to meet healthcare needs. In addition, we believe innovation and adoption of new ways of operating prompted by these desperate times bodes well for the sector participants both in the short and long runs.